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Disulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer
treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-
encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA
has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the
half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver
cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also
demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA
approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Primary liver cancer is the fifth most common neoplasm and HCC is high in Asia and increasing in the Western world in the
the third most common cause of cancer-related death
worldwide.1 Hepatocellular carcinoma (HCC) accounts for
70%-80% of cases of primary liver cancer.2 The incidence ofWe acknowledge support from Marie-Curie IIF Program (PIIF-GA-
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licenses/by-nc-nd/4.0/).past decade. Although the therapeutic outcomes in many cancers
have been improved significantly, the prognosis of advanced
HCC remains very dismal.3 Chemoresistance and metastasis are
the major hindrances for the treatment of advanced HCC. HCC
cells are resistant to all currently available anticancer drugs.
Sorafenib (Nexavar) is the sole drug showing marginal efficacy
in HCC with only approximately 3 month improvement for
overall survival.4 Therefore, development of efficacious chemo-
therapeutic drugs is of significant clinical importance for
treatment of the advanced HCC.cess article under the CC BY-NC-ND license (http://creativecommons.org/
Figure 1. In vitro characterization of DS-PLGA. (A) The scheme of DS metabolism and reaction with copper(II). (B) Scanning electron micrographs of PLGA
and DS-encapsulated PLGA (DS-PLGA). (C) The influence of serum concentration on the size of DS-PLGA. (D) The influence of serum concentration on zeta
potential. (E) In vitro release profiles of DS. (F) In vitro half-life of DS in horse serum. (G) The in vitro half-life of free DS and DS-PLGA in horse serum.
**P b 0.01.
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population of cancer stem-like cells (CSCs). HCC CSCs can be
identified by detection of the expression of stem cell markers e.g.
ALDH, CD133, CD90, CD44, EpCAM, and CD13.5 Previous
studies suggest that CSCs are maintained by the hypoxic
milieu,6,7 quiescent and highly resistant to currently available
chemotherapeutic agents. Conventional anticancer drugs elimi-
nate bulk of cancer cells but could not eradicate CSCs, which
become the source of the cancer recurrence and metastasis.
Therefore, development of efficacious CSC-targeting drugs may
improve the therapeutic outcomes of HCC.
New drug development is a time and cash consuming
procedure. This leads to the current interest in drug repositioning.8
Previous studies demonstrate that disulfiram (DS), a commercially
available anti-alcoholism drug,9 is highly cytotoxic to a wide range
of cancer cell lines10–13 and enhances conventional anticancer
drug-induced apoptosis in colon, breast and brain cancer cell
lines.10,14–16 Importantly, DS is highly cancer specific and
specifically inhibits the activity of aldehyde dehydrogenase
(ALDH), a functional marker of CSCs and reactive oxygen
species (ROS) scavenger17,18 to eliminate CSCs.Although the anticancer activity of DS has been reported for
almost 3 decades, its translation into clinical cancer treatment is
severely limited by its very short half-life in the bloodstream.19
The anticancer activity of DS is copper (Cu), zinc and some other
divalent transitional metal elements dependent.11,20–22 DS is
quickly reduced to diethyldithiocarbamate (DDC), a strong
chelator of copper(II). The reaction between DDC and Cu(II)
generates ROS which are highly toxic to cancer cells. Due to the
extremely short lifespan of ROS in human tissues,23 the
extracellular ROS can target cancer cells only when the reaction
takes place within the cancer tissues.22,24 DDC-Cu, the final
product of the DS and Cu reaction, can also penetrate into cancer
cells and induce apoptosis.22 The sulfhydryl group of DDC is
essential (Figure 1, A) for chelation of Cu(II) by DDC. The
currently available oral version of DS is quickly reduced to DDC
and the sulfhydryl group of DDC is promptly destroyed by
glucuronidation, methylation and degradation in the bloodstream
of the portal vein.25 This may introduce the discrepancy between
the anticancer activity of DS in vitro, in vivo and in patients. In
order to translate DS into cancer therapeutics, intact sulfhydryl
group of DS or DDC must be protected in the bloodstream and
Figure 1 (continued).
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ROS and form DDC-Cu (Figure 1, A). We previously showed
that encapsulation of DS into liposome extends the half-life of
DS and improves its in vivo anticancer efficacy in breast cancer
mouse model.6
The purpose of this study is to develop a long circulating poly
lactic-co-glycolic acid (PLGA) encapsulated DS (DS-PLGA) to
achieve longer circulating time and improve the anticancer
efficacy of DS.Methods
Materials
The HCC cell lines Huh7 and PLC/PRF/5 were purchased
from ATCC (Middlesex, UK). DS, 5-fluorouracil (5-FU), copper
chloride (CuCl2), copper gluconate (CuGlu), poly
lactic-co-glycolic acid (PLGA), poly(vinyl acetate), cyano-
methyl diphenylcarbamodithioate (PVA), dichloromethane,
poly-2-hydroxyethyl methacrylate (poly-HEMA) and bovine
serum albumin (BSA) were purchased from Sigma (Dorset, UK).
DMEM and fetal calf serum (FCS) were supplied by Lonza
(Wokingham, UK). Ki-67 and BAX antibodies were purchased
from Cell Signaling (Danvers, MA, USA). NFkBp65 and
ALDH1 antibodies were from Abcam. Sorafenib was from
BioVision (CA, USA). Cell culture inserts were purchased from
Fisher (Loughborough, UK). Lipo-DS was provided by Prof.
Xing Tang (Shenyang Pharmaceutical University, China).Preparation and characterization of DS-PLGA nanoparticles
The DS loaded nanoparticles were prepared using an
emulsion–solvent evaporation method. PLGA (200 mg) and
DS (20, 40, 50, 100 or 150 mg) were dissolved in 10 mL of
dichloromethane, and then mixed with 20 mL of 2.5% PVA
aqueous solution. This mixture was homogenized for 1 min by
vortex and then sonicated using a microtip probe sonicator set at
70% power output (XL 2002 Sonicator® ultrasonic liquid
processor) for 3, 4 or 5 min to produce the oil-in-water emulsion.
The organic phase was evaporated for 5 h at room temperature.
The nanoparticles were recovered by centrifugation
(10,000 rpm, 20 min, Hitachi). The nanoparticles were washed
twice with water. The purified nanoparticles were freeze-dried in
5% sucrose.
The size distribution and zeta potential of DS-PLGA were
measured by DLS using a Zetasizer (ZS90, Malvern, U.K.) with
a scatter angle of 90° at 25 °C. The morphology of nanoparticles
was observed by scanning electron microscopy (SEM) (JEOL
JSM T330A). A drop of the nanoparticle suspension was placed
on a metallic surface. After drying under vacuum, the sample
was coated with a gold layer.
Measurement of encapsulation efficiency, drug loading content,
cumulative release and the in vitro half-life of DS-PLGA
The amount of non-entrapped DS was determined using
HPLC by UV detection set at 275 nm (SHIMADZU LC-20).
The mobile phase was a mixture of methanol:water (70:30%)
Table 1
Physicochemical parameters of PLGA and DS loaded PLGA nanoparticles.
Nanoparticles Drug loading content (%) Encapsulation efficiency (%) Size (nm) Zeta potential (mV)
Empty PLGA – – 131.8 ± 6.9 22.3 ± 0.8
DS-PLGA 27.67 ± 3.47 78.92 ± 2.16 136.2 ± 6.2 21.7 ± 0.96
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using a Phenomenex C18 column (250 mm × 4.6 mm, 5 μm).
The amount of DS entrapped in the nanoparticles was
determined after their dissolution in dichloromethane. After
evaporation of dichloromethane at room temperature, DS was
dissolved in pure ethanol. The supernatants were passed through
a membrane filter (pore size 0.22 μm, Millipore) before HPLC
measurements. The cumulative release profile of DS-PLGA was
measured in 0.1 M phosphate buffer solution (PBS, pH 7.4) with
0.5% Tween 80 at 37 °C. In brief, 10 mg DS-PLGA was
suspended in 25 ml PBS-Tween80 solution with continuously
shaking (100 rpm min−1) at 37 °C. At indicated time intervals,
500 μl of the release media was collected and centrifuged at
14,000 rpm for 10 min at room temperature to remove the
PLGA nanoparticles with unreleased DS. The DS concentrations
in the supernatant were measured using HPLC and equal volume
of fresh media was replenished. The drug loading content (DLC)
and encapsulation efficiency (EE) of DS in the PLGA
nanoparticles were calculated using the following equations.
DLC %ð Þ¼Weight of DS in PLGA=Weight of the whole DS‐PLGA
100%
EE %ð Þ¼ Weight of total DS–Weight of free DSð Þ=Weight of total DS
100%
To examine the half-life of DS in vitro, free DS or DS-PLGA
(100 μl at a concentration of 3 mg/ml) was added into an
Eppendorf tube containing 300 μl of horse serum with shaking at
37 °C. The Eppendorf tubes were collected and protein
precipitated by adding 300 μl of absolute methanol at different
time intervals. The PLGA nanoparticles with unreleased DS
were removed by centrifugation at 14,000 rpm for 10 min at
room temperature. The DS in the supernatant was determined by
HPLC measurement.
In vitro cytotoxicity of DS-PLGA to HCC cells
The PLC/PRF/5 and Huh7 HCC cell lines were cultured in
DMEM supplemented with 10% FCS, 50 units/ml penicillin,
and 50 μg/ml streptomycin. For in vitro cytotoxicity assay, the
overnight cultured cells (5000/well) in 96-well flat-bottomed
microtiter plates were exposed to drugs for 72 h in normoxic or
hypoxic condition and subjected to a standard MTT assay.16
Analysis of the combinational effect of 5-FU + DS-PLGA/Cu
and sorafenib + DS-PLGA/Cu
The HCC cells were cultured at 5000 cells/well in 96-well
plates overnight and then exposed to various concentrations of
5-FU, sorafenib, DS-PLGA/Cu1μM, 5-FU or sorafenib in
combination with DS-PLGA/Cu1μM at a constant ratio of
5-FU:DS-PLGA and sorafenib:DS-PLGA of 1000:1 and 100:1respectively. The cells were exposed to different drug combina-
tions for 72 hours subjected to MTT analysis.16 The IC50s from
one and two-drug-treated cells were determined. The combina-
tional cytotoxicity was analyzed by CI-isobologram program
using CalcuSyn software (Biosoft, Cambridge, UK).26 The
combination index (CI) was determined by mutually exclusive
equations.
Flow cytometric detection of ALDH activity and CD133
expression
The ALDH positive population was detected by
ALDEFLUOR kit (StemCell Tech., Durham, NC, USA)
following the supplier's instruction. The cells (2.5 × 105) were
analyzed after stained in ALDH substrate containing assay buffer
for 30 min at 37 °C. Diethylaminobenzaldehyde (DEAB), a
specific ALDH inhibitor, treated cells were used as a positive
control.
To detect the expression of CD133 positive cells, the cells
(2.5 × 105) were incubated with CD133 antibody (BD Pharmin-
gen, Oxford, UK) for 30 min at 4 °C. Unbound antibodies were
washed off with 2% FCS HBSS (Sigma). After staining for no
longer than 1 h, the positively stained population (10,000 events)
was detected using a BD Accuri™ C6 flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) with 488-nm blue laser
and standard FITC 530/30 nm bandpass filter.
Flow cytometric detection of apoptosis
DNA content was used to detect the apoptotic cells. Briefly,
cells (1 × 106) were exposed to drugs and harvested by
trypsinization. The cells were fixed in 70% ethanol and then
incubated with RNase A (100 μg/ml) and propidium iodide
(2.5 mg/ml) for 30 min. The DNA content data from 10,000
cells in each sample was collected by a BD Accuri™ C6 flow
cytometer and analyzed using a CellQuest software (BD
Biosciences, Oxford, UK).
Clonogenic assay
The overnight cultured cells (5 × 104) were exposed to
DS-PLGA (50 nM), CuCl2 (1 μM), DS-PLGA (50 nM) plus
CuCl2 (1 μM), 5-FU (200 μM) or sorafenib (20 μM) for 6 h.
The cells were collected and sub-cultured in 6-well plates
containing drug-free medium at a cell density of 2.5 × 103/well.
After 10 days culture, the clonogenic cells were determined by
counting the colonies containing at least 50 cells.
In vitro HCC sphere cell culture
To culture the HCC spheres, cells were cultured in
poly-HEMA coated ultra-low adherence flasks or plates to
prevent cell adhesion. The spheres were cultured, at a density of
Figure 2. In vitro cytotoxicity of DS-PLGA in HCC cell lines. The PLC/PRF/5 (A) and Huh7 (B) HCC cell lines were exposed to drugs for 72 h and subjected
to typical MTT cytotoxicity assay. n = 3, the vertical bars represent SD. (C) PLC/PRF/5 and Huh7 cell lines were subjected to different treatments for 4 h. The
DNA contents were measured by flow cytometry analysis. Typical histograms are presented. n = 3; **P b 0.01.
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DMEM-F12 supplemented with B27 (Invitrogen, Paisley, UK),
20 ng/ml epidermal growth factor (EGF, Sigma), 10 ng/ml basic
fibroblast growth factor (b-FGF, R & D System, Abingdon,
UK)]. After 7 days of culture, the spheres were subjected to
different treatments.
In vitro migration and invasion assay
Cell invasion and migration assays were performed using cell
culture inserts (Millipore) coated with or without Matrigel (BD
Bioscience, Bedford, MA, USA), respectively. Cells (5 × 104)
were resuspended in 200 μl serum-free DMEM and placed in
upper chamber of the insert. The lower chamber was filled with
medium containing 10% FCS. After 48 h incubation at 37 °C,
migrated cells were fixed by methanol and stained in 0.5% crystal
violet. Cells in six random microscopic fields were counted.
HCC xenograft and in vivo metastasis experiments
Five-week-old female BALB/c Nu/Nu athymic nude mice
(Biotechnology & Cell Biology Shanghai, China) were housed
under pathogen-free conditions according to the Third Military
Medical University (TMMU) animal care guidelines and the
animal experiments were reviewed and approved by the Ethical
Committee of TMMU. PLC/PRF/5 cells (5 × 105) were
subcutaneously injected at one front flank of the mice. When
the tumor volume (V) reached ~200 mm3, the tumor bearing
mice were randomly subdivided into 8 groups (8 mice/group): 1.
Control: no treatment; 2. Copper gluconate (CuGlu) 6 mg/kg
p.o.; 3. Empty PLGA i.v.; 4. Free DS 10 mg/kg p.o. + CuGlu
6 mg/kg p.o.; 5. DS-PLGA 2.5 mg/kg i.v. + CuGlu 6 mg/kg
p.o.; 6. DS-PLGA 5 mg/kg i.v. + CuGlu 6 mg/kg p.o.; 7.
DS-PLGA 10 mg/kg i.v. + CuGlu 6 mg/kg p.o.; 8. DS-Lipo
10 mg/kg i.v. + CuGlu 6 mg/kg p.o. We chose copper gluconate
for in vivo study because it showed similar effect in vitro
(Table 2) and is more tolerable by animal. The animals were
treated 3 times/week for successive 3 weeks. The xenograft sizewas recorded trice per week. The tumor volume was calculated
by the following formula: V = (L × W2) × 0.5, where L is the
length and W is the width of the tumor. After 3 weeks, the
animals were sacrificed. The tumors were removed, photo-
graphed and subjected to further analysis.
The in vivo lung metastasis mouse model was established by
injecting 5 × 106 single-cell suspension of PLC/PRF/5 cells (in
200 μl of PBS) into the tail vein. After 2 weeks, the mice were
treated 3 times/week with 10 mg/kg DS-PLGA i.v. and CuGlu
6 mg/kg p.o. for 4 successive weeks. The mice were sacrificed
two days after the last treatment. The lungs were removed and
formalin-fixed for paraffin embedment and H&E staining.
Immunohistochemistry and H&E staining
The sections from paraffin embedded tumor and normal
tissues were stained with primary antibodies (Ki-67, 1:200;
BAX, 1:200; NFkBp65, 1:200; ALDH1, 1:200) then biotinyl-
ated secondary antibody and followed by incubation in ABC
reagent (Dako Labs, Cambridgeshire, UK). For H&E staining,
the paraffin-embedded sample slides were stained with hema-
toxylin and eosin and the slides were mounted with coverslips
using Permount (Fisher Sci, Loughborough, UK).
Statistical analysis
The statistical significance of treatment outcomes was
assessed using the Student's ttest and one-way ANOVA;
P b 0.05 was considered statistically significant in all analyses.Results
Physicochemical characterization of DS loaded PLGA nano-
particles
The influence of PLGA:DS ratio and sonication/homogeniz-
ing time on the EE, DLC and nanoparticle size were examined.
The PLGA:DS ratio of 2:1 (w/w) and 4 min of sonication
Figure 2 (continued).
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most narrow size (131.8 ± 6.9 and 136.2 ± 6.2 nm) and
satisfactory zeta potential (−22.3 ± 0.8 and −21.7 ±
0.96 mV) distribution between the empty and DS loaded
PLGA nanoparticles (Table 1 and Supplementary Tables S1
and S2). The SEM image showed that the DS-PLGA was in
analogous spherical shapes (Figure 1, B). DS-PLGA showed
high EE (78.92 ± 2.16%) with satisfactory DLC (27.67 ±
3.47%).
To determine the stability and release of DS in DS-PLGA, the
DS-PLGA was incubated in 1%, 5% and 10% BSA solutions at
37 °C. The particle size was increased in a time and BSA
concentration-dependent manner (Figure 1, C). The zeta potential
of the DS-PLGA was also examined after 24 h incubation inBSA solution. At a physiological concentration of BSA (5%),
the DS-PLGA maintained a satisfactory particle size (162 nm)
and zeta potential (−15.8 mV) for at least 8 and 24 h,
respectively (Figure 1, D). The DS-PLGA showed very good
dispersibility.
In vitro cumulative release and half-life of DS in serum
The cumulative drug release was performed over a period of
7 days in a 0.5% Tween 80 PBS solution (pH 7.4) at 37 °C. The
DS concentrations at different time lengths were examined.
Results demonstrate a very steady and sustained release of DS
over 7 days. Around 20% of DS was released within 24 h and
reached a 40% release at day 4, which was maintained until day 7
Figure 3. Hypoxia induced expression of CSC marker and chemoresistance in HCC cells. (A) and (B) PLC/PRF/5 and Huh7 cells were cultured in either
normoxic or hypoxic condition for 5 days. The ALDH activity and expression of CD133 were examined by flow cytometry. (C) The specificity of ALDH
detection was confirmed by DEAB inhibition. (D–F) After 72 h exposure, the cytotoxicity of 5-FU and sorafenib was determined in HCC cell lines cultured at
normoxic and hypoxic conditions. **P b 0.01.
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Figure 4. DS-PLGA inhibited hypoxia-induced CSC marker expression, eradicated sphere forming ability and clonogenicity in HCC cell lines. (A) Percentage
of ALDH and CD133 positive cells. The HCC cells were cultured at hypoxic condition for 5 days and subjected to different treatments for 4 h (DS represents
DS-PLGA). (B) After exposure of sphere cells to different drugs for 24 h, the ALDH and CD133 positive population was examined by flow cytometry (DS
represents DS-PLGA). (C) and (D)DS-PLGA/Cu blocked the sphere-forming ability in HCC cell. (E) and (F)DS-PLGA/Cu induced apoptosis in sphere cells.
(G) and (H) DS-PLGA/Cu eradicated clonogenicity in HCC cell lines. n = 3; **P b 0.01.
648 Z. Wang et al / Nanomedicine: Nanotechnology, Biology, and Medicine 13 (2017) 641–657(Figure 1, E). To determine the half-life of DS in vitro, the free
DS and DS-PLGA (100 μg/ml) were dispersed into horse serum
at 37 °C. The free DS was rapidly degraded to undetectablelevels within 30 seconds (Figure 1, F). In contrast, DS
commenced its release from PLGA at 2 min, equivalent to
34.23 ± 3.38% of the initial drug loading and peaked in 4 min at
Figure 4 (continued).
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The half-life of DS-PLGA in serum (7 h) is significantly longer
than that of free DS (Figure 1, G).
In vitro cytotoxicity of DS-PLGA NPs in HCC cells
The cytotoxicity of DS-PLGA and free DS in PLC/PRF/5 and
Huh7 HCC cell lines was compared by MTT assay. CuCl2
(1 μM) was supplemented in all the experiments. The in vitro
cytotoxicity of DS-PLGA is slightly lower than that of the free
DS but no significant difference between the IC50s of DS-PLGA
(Huh7, 30.69 ± 3.83 nM; PLC/PRF/5, 49.33 ± 4.11 nM) and
free DS (Huh7, 25.34 ± 3.21; PLC, 45.25 ± 3.52 nM)
(P N 0.05) (Figure 2, A and B). After exposure to DS-PLGA
(50 nM) and CuCl2 (1 μM) for 4 h, the apoptotic cells (sub-G1
population) were identified by DNA content assay using flow
cytometry analysis. Background levels of spontaneous apoptotic
cells were detected in untreated (2.47% and 3.31%) and PLGA
empty nanoparticles plus CuCl2 treated (2.58% and 3.14%)
Huh7 and PLC/PRF/5 cell lines respectively. In contrast,
massive apoptotic cells (15.68% and 44.47%) were detected in
DS-PLGA/CuCl2 treated Huh7 and PLC/PRF/5 cell lines,
respectively (Figure 2, C).Hypoxia induced CSC traits and resistance to conventional
anticancer drugs
To determine the effect of hypoxia on CSC population, two
CSC markers, ALDH and CD133, were examined in hypoxia
and normoxia cultured HCC cell lines. The enhanced ALDH
activity and elevated expression of CD133 indicated that the
CSC population in PLC/PRF/5 and Huh7 cell lines was
significantly enlarged by hypoxic environment (Figure 3, A
and B). The specificity of ALDH detection was confirmed by
DEAB inhibition (Figure 3, C). Furthermore, we examined the
chemosensitivity of HCC cell lines at hypoxic condition. When
cultured at 1% O2, the HCC cell lines were significantly resistant
to 5-FU and sorafenib (Figure 3, D-F).
DS-PLGA inhibited hypoxia-induced CSCs and synergistically
enhanced cytotoxicity of 5-FU and sorafenib
Incubation of HCC cells with DS-PLGA (20 nM) and CuCl2
(1 μM) for 24 h significantly reduced the ALDH+ and CD133+
cell population in PLC/PRF/5 and Huh7 cell lines suggesting the
sufficient inhibitory effect of DS-PLGA on hypoxia-induced
CSCs. In contrast, 5-FU (200 μM), sorafenib (20 μM), Cu or
Table 2
Cytotoxicity of 5-FU, sorafenib, DS-PLGA, 5-FU/DS-PLGA and sorafenib/DS-PLGA in HCC cell lines.
Huh7 PLC/PRF/5
IC50s
5-FU (μM) 103.26 (6.21) 122.84 (8.14)
Sorafenib (μM) 22.88 (1.26) 30.89 (2.61)
DS-PLGA (nM) + CuCl2 30.69 (3.83) 49.33 (4.11)
DS-PLGA (nM) + CuGlu 38.6 (5.88) 35.5 (7.98)
5-FU (μM)/DS-PLGA (nM) + CuCl2 18.74 (1.09)/18.74 (1.09) 27.56 (1.09)/27.56 (1.09)
Sorafenib (μM)/DS-PLGA (nM) + CuCl2 2.21 (0.19)/22.07 (1.88) 3.08 (0.12)/30.77 (1.17)
CI Values
5-FU/DS
IC50 0.001 0.003
IC75 0.001 0.003
IC90 0.002 0.002
Sorafenib/DS
IC50 0.006 0.051
IC75 0.010 0.094
IC90 0.018 0.178
The figures are IC50s and CI values, respectively. The numbers in the parentheses are the SD; n = 3. CI values: 0.9-1.1additive effect; 0.8-0.9slight synergism;
0.6-0.8moderate synergism; 0.4-0.6synergism; 0.2-0.4 strong synergism. Both CuCl2 and CuGlu are 1 μM.
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(Figure 4, A). Furthermore, the combinational effect of
DS-PLGA/Cu and 5-FU or sorafenib was examined using
CI-isobologram assay. In combination with DS-PLGA, the in
vitro cytotoxicity of 5-FU and sorafenib was significantly
enhanced. CI-isobologram analysis indicates very significant
synergistic combinational effect among 5-FU, sorafenib and
DS-PLGA/Cu in a wide range of IC values (IC50 − IC90) (Table 2,
Figures S1 and S2).
DS-PLGA inhibited expression of CSC markers in spheroid
culture and eradicated sphere-forming and clonogenic abilities
CSCs can form spheres in stem cell culture conditions.
Sphere-forming ability is widely accepted as a golden standard
for in vitro analysis of stemness of CSCs.27 The effect of
different treatments on sphere-forming ability was examined. A
significantly higher percentage of ALDH and CD133 positive
CSC population was detected in spheroid cells (Figure 4, B). The
ALDH and CD133 positive CSC population in the spheres was
significantly reduced after exposure to DS-PLGA (20 nM) and
Cu (1 μM) for 4 h but not affected by other treatments. The
sphere-forming ability was completely abolished after exposure
to DS-PLGA (20 nM) plus Cu (1 μM) for 6 h. No inhibiting
effect was observed in 5-FU and sorafenib treated cells (Figure 4,C
and D). The DS-PLGA/Cu treated HCC CSCs underwent
apoptosis (Figure 4, E and F). We next performed clonogenic
assay, a traditional method to determine the self-renewal
capacity, cancer cell regeneration and CSC traits,28 to examine
the ability of DS-PLGA/Cu to induce the ‘reproductive death’ in
HCC cell lines. The monolayer-cultured PLC/PRF/5 and Huh7
cells were exposed to 5-FU (200 μM), sorafenib (20 μM),
CuCl2 (1 μM), DS-PLGA (50 nM) or DS-PLGA (50 nM) plus
CuCl2 (1 μM) for 6 h. The treated cells were collected and
cultured in 6-well plates containing drug-free medium at a
cell density of 500 cells/well for another 10 days. There
was no significant difference in colony numbers when the
control group was compared with 5-FU, sorafenib andCuCl2 treated groups. In contrast, the colonies in DS-PLGA/
Cu treated group were completely eradicated in both cell lines
(Figure 4, G and H).
DS-PLGA blocked migration and invasion ability of hypoxic
and sphere-cultured cells in vitro
CSCs have high metastatic ability, another key event
responsible for the very poor prognosis of the advanced HCC
patients. Because DS-PLGA/Cu shows very strong inhibiting
effect on CSC traits in HCC cell lines, we further examined its
effect on cell migration and invasion in vitro. The hypoxia
(Figure 5, A and B) and CSC (Figure 5, C and D) induced
migration and invasion was significantly inhibited by DS-PLGA/
Cu at an extremely low concentration (5 nM) which is only 1/8
to 1/10 of the IC50 concentrations for Huh7 and PLC/PRF/5
respectively. At this concentration, no cytotoxicity was observed
in both cell lines.
In vivo anti-HCC efficacy of DS-PLGA in mouse xenografts
To assess anti-tumor activity in vivo, 2.5 mg/kg, 5 mg/kg and
10 mg/kg DS-PLGA was intravenously injected into the tail veins
of theHCC xenograft bearingmice. In comparisonwith the control
group, 10 mg/kg DS-PLGA significantly inhibited tumor size and
tumor weight (Figure 6, A and B). An equivalent oral dose of DS/
Cu or Lipo-DS i.v./oral-Cu, had no effect on the xenografts. This
result indicates that the PLGA encapsulation protected DS from
degradation in the bloodstream and delivered the intact DS to
cancer tissues. DS-PLGA/Cu treatment inhibited the expression of
NF-κB p65 and ALDH in the HCC xenografts (Figure 6, C). No
significant mouse body weight difference between the control and
treated groups and no cytotoxic effect was observed in the vital
organs e.g. lung, liver and kidney (Figure 6, D and E).
DS-PLGA and copper blocks HCC lung metastasis in vivo
The very encouraging in vitro anti-migration and invasion
data prompted us to examine the anti-metastatic effect of
Figure 5. DS-PLGA inhibited migration and invasion ability in hypoxia- and sphere-cultured HCC cells. (A) and (B) DS-PLGA/Cu inhibited migration and
invasion of hypoxic HCC cells. After 7 days hypoxic culture, the HCC cells were subcultured in a transwell containing different chemicals at hypoxic condition
for 48 h (DS represents DS-PLGA). (C) and (D) DS-PLGA/CuCl2 inhibited migration and invasion of HCC CSCs. After 7 days sphere culture, the HCC cells
were subcultured in a transwell containing different chemicals at hypoxic condition for 48 h. n = 3; **P b 0.01.
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Figure 6. DS-PLGA + Cu inhibited the growth of HCC derived xenografts and the in vivo effect on different biological pathways. (A) The growth curves of
tumor size. The drugs were administered 3 times/week for successive 3 weeks. (B) The weight of tumors at the end of experiment. Control: no treatment, Cu:
CuGlu p.o., Empty NPs: Empty PLGA i.v., Free DS + Cu: DS p.o. + CuGlu p.o.; PLGA + Cu: DS-PLGA i.v. + CuGlu p.o., Lipo DS + Cu: Liposome DS
i.v. + CuGlu p.o. (C) The effect of DS-PLGA (10 mg/kg) plus CuGlu (6 mg/kg) on the protein expression of Ki67, BAX, NF-κB and ALDH in HCC
xenografts (×400 magnification). (D) The body weight changes during the experimental period. (E) Representative histopathological images of lung, liver and
kidney in DS-PLGA plus CuGlu treated mice (H&E staining, × 400 magnification).
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HCC cells was completely blocked by combinational application
of DS-PLGA and CuGlu (Figure 7). Cancer nodules and
micro-metastasis were observed in the control group but not in
the treated animals. All the in vivo experiments were performed
with the guidelines approved by the Institutional Animal Care and
Use Committee of the Fourth Military Medical University.Discussion
Only 5-25% of new oncology drugs in clinical development
are actually reaching the market.8,29 This has led to an increasing
appreciation of the potential of repurposing known drugs for
cancer treatment. DS is highly cytotoxic in several types of
cancer cells in vitro,6,10,15,16,30–32 whereas oral administration of
free DS does not inhibit tumor growth in vivo.33 Recent
publication suggests that the intact sulfhydryl group is essential
for the anticancer function of DS.22,24 The degradation of DS in
the bloodstream destroys the sulfhydryl group making DS loseits cancer targeting ability. The degradation of DS in the serum
kinetically results from a covalent interaction of this drug with
the free sulfhydryl of serum albumin. The half-life of DS pH 7.4
is 1-1.5 minutes.19,34,35,36,37 This may introduce the discrepancy
between the anticancer activities in vitro, in vivo and in
clinic (ClinicalTrials.gov: NCT00256230, NCT00742911,
NCT01118741). Nanomedicine can protect and deliver
drugs in the bloodstream.38 The in vivo anticancer efficacy
of DS can be improved by liposomal encapsulation (half-life
~25 min).6,33 In this study, we successfully extended the
half-life of DS to ~7 h by encapsulation of DS into PLGA
(Figure 1, G). We achieved very satisfied EE, DLC, nano-particle
size and dispersibility (Table 1). The DS encapsulated nano-
particles are stable in physiological concentrations of BSA and the
release of DS was steadily controlled at 37 °C. Importantly, after
8 h incubation, the DS concentration in the serum still remained at
~40 μM (12 μg/ml, Figure 1, F), which is markedly higher than the
IC50s ofDS in awide rangeof cancer types (~50-500 nM).
6,10,15,16,30–32
DS-PLGA/Cu induced HCC cell apoptosis and the in vitro
cytotoxicity of DS-PLGA/Cu were comparable to the free DS
Figure 7. DS-PLGA + CuGlu blocked lung metastasis. (A) The images of lung metastatic nodules (black arrows). (B) The cancer nodule number in lung. (C)
Representative H&E staining microscopic images showing the histology of metastatic nodules in mouse lung.
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strategy for protection of the sulfhydryl group inDS and translation
of DS into cancer treatment.
HCC is resistant to all currently available anticancer drugs
with only very marginal response to sorafenib.4 It has been
widely accepted that CSCs display significant resistance to
cytotoxic drugs with different resistant mechanisms.39 Hypoxia
is a common feature of HCC. The median partial pressure of O2
in HCC is 6 mmHg as compared to 30 mmHg in normal liver
tissues.40 Emerging evidence suggests that hypoxia plays pivotal
roles in chemoresistance.41 The hypoxic condition in the stem
cell niche is essential for maintaining the stemness in CSCs.42
Therefore inhibition of hypoxia-induced CSCs may sensitize
cancer cells to conventional anticancer drugs. Previous studies
indicate that DS targets CSCs and sensitizes several types of
cancers to conventional anticancer drugs.6,10,16,30,32,43,44 Our
results demonstrated that hypoxia increased CSC population in
HCC cell lines. The hypoxic cells were highly resistant to 5-FU
and Sorafenib (Figure 3). DS-PLGA/Cu synergistically en-
hanced the cytotoxicity of 5-FU and sorafenib in HCC cells
(Table 2 and Figures S1 and S2). At a very low concentration
(20 nM), DS-PLGA/Cu significantly inhibited the ALDH and
CD133 positive CSC population in both hypoxia-induced and
spheroid cultured HCC cell lines (Figure 4, A and B). The sphere
forming and clonogenic ability in HCC cell lines was completely
abolished by very low concentration of DS-PLGA/Cu. In
contrast, 5-FU and sorafenib had no effect on CSC population.
DS-PLGA/Cu also very strongly in vivo inhibited NF-κB and
ALDH activity which are highly responsible for the stemness of
CSCs6,16,30 and efficaciously targeted HCC xenografts at an
equivalent to 1/5 of the human antialcoholism dose. The effect of
DS-PLGA/Cu on HCC xenografts was dose dependent (Figure 6,
A and B). In consistence with our previous study,6 no toxicity was
observed in the vital organs of the DS-PLGA/Cu treated animals
(Figure 6, E).
HCC has been shown the hypoxia-induced epithelial-
to-mesenchymal transition (EMT), a typical character of CSCs
involving in metastasis.45,46 Liver transplantation is carried out to
treat HCC, especially in the early stage. However, due to the
extrahepatic organ micrometastasis, the incidence of postoperative
recurrence andmetastasis is very high (60-100%).47 Lung remains
themost frequent site for HCCmetastasis. At the time of diagnosis,
most patients have multiple pulmonary or systemic metastasis.48
There are still no effective systemic therapies available for the
metastatic HCC. Therefore development of a drug with anti-
metastatic effect will improve HCC treatment.49,50 DS-PLGA/Cu
showed very strong anti-metastatic effect on HCC in vitro (Figure 5)
and in vivo (Figure 7), highly in line with our in vivo metastatic
lung cancer data (unpublished data). Therefore,DS-PLGA is potentially
an effective anti-metastatic drug for HCC treatment.
In conclusion, we showed that the DS-PLGA has very
satisfactory EE, DLC, in vitro controlled release and half-life.
DS-PLGA and copper showed very strong inhibiting effect on
CSCs and synergistic cytotoxicity with 5-FU and sorafenib. It
also manifests very promising anticancer efficacy and
anti-metastatic activity in HCC mouse model. Our results
suggest that nano-controlled delivery system may lead to fast
translation of DS into liver cancer treatment.Acknowledgements
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